| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-11-1991 |
| P698 | PubMed publication ID | 22238246 |
| P2093 | author name string | Ian Walters | |
| Richard S Finn | |||
| Ho Yeong Lim | |||
| Christine Baudelet | |||
| Yoon-Koo Kang | |||
| Mary Mulcahy | |||
| Blase N Polite | |||
| Joong-Won Park | |||
| Demetrios Manekas | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 2090-2098 | |
| P577 | publication date | 2012-01-11 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma | |
| P478 | volume | 18 |
| Q92855692 | A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma |
| Q87691280 | A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma |
| Q34781699 | A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. |
| Q33419633 | A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. |
| Q44681461 | A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy |
| Q38697243 | Advances in Local and Systemic Therapies for Hepatocellular Cancer |
| Q38210345 | Advances in managing hepatocellular carcinoma |
| Q38521011 | Advances in targeted therapies for hepatocellular carcinoma in the genomic era. |
| Q36788158 | Akt and mTORC1 have different roles during liver tumorigenesis in mice |
| Q47954829 | An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma |
| Q28075305 | Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma |
| Q36804518 | Antiangiogenic therapies for advanced hepatocellular carcinoma |
| Q38160838 | Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety |
| Q57762740 | Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial |
| Q35141906 | Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling. |
| Q38048883 | Brivanib: a review of development |
| Q35501246 | Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges |
| Q37435638 | Clinical trials in hepatocellular carcinoma: an update |
| Q38166329 | Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use. |
| Q27026036 | Current systemic treatment of hepatocellular carcinoma: A review of the literature |
| Q44481786 | Diagnosis of and therapy for hepatocellular carcinoma |
| Q39116687 | Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. |
| Q38184582 | Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy |
| Q35739362 | Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma |
| Q33648955 | Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma |
| Q33411190 | Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib |
| Q36561567 | Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies |
| Q38207012 | Hepatocellular carcinoma review: current treatment, and evidence-based medicine |
| Q28084046 | Hepatocellular carcinoma: Where there is unmet need |
| Q33895113 | Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies |
| Q27005850 | Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy |
| Q40707153 | Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma |
| Q26798462 | Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy |
| Q37049104 | Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma |
| Q48105164 | Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation |
| Q37175085 | Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours |
| Q38264616 | Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art |
| Q47121307 | Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review |
| Q38151670 | Molecular targeted therapy for hepatocellular carcinoma: current and future |
| Q26766689 | Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? |
| Q38233004 | Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. |
| Q26738548 | New advances in targeted gastric cancer treatment |
| Q38074429 | New agents on the horizon in hepatocellular carcinoma |
| Q89528234 | New landscapes and horizons in hepatocellular carcinoma therapy |
| Q34438331 | Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently |
| Q38062022 | Pathways and targets in hepatocellular carcinoma |
| Q36598514 | Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma |
| Q38864396 | Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment |
| Q38977239 | RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. |
| Q38264330 | Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review. |
| Q35911679 | Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib |
| Q87226010 | Sorafenib use in hepatocellular carcinoma: more questions than answers |
| Q92669957 | Systemic targeted therapy beyond sorafenib |
| Q38150875 | Systemic therapies in hepatocellular carcinoma: present and future |
| Q26865844 | Systemic therapy of hepatocellular carcinoma: current status and future perspectives |
| Q38933836 | Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs? |
| Q35759606 | Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications |
| Q38114062 | Targeted therapies in the treatment of advanced hepatocellular carcinoma |
| Q42343453 | Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. |
| Q38631272 | Targeting angiogenesis in endometrial cancer - new agents for tailored treatments. |
| Q37274132 | Targeting the tumor microenvironment: from understanding pathways to effective clinical trials |
| Q47121517 | The 4th Asia-Pacific Primary Liver Cancer Expert Meeting |
| Q46622652 | The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? |
| Q37606028 | The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy |
| Q50951764 | The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. |
| Q91784365 | Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review |
| Q38858806 | Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside. |
| Q47832831 | Treatment options after sorafenib failure in patients with hepatocellular carcinoma. |
| Q64116366 | Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report |
| Q26797535 | Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma |
| Q38908811 | mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma |
Search more.